Summary
Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rentschler R, Burgess M, Byers R: Chemotherapy of malignant major salivary gland neoplasms. A 25-year review of the M.D. Anderson Experience. Cancer 4:619–624, 1977
Vermeer RJ, Pinedo HM: Partial remissions of advanced adenoid cystic carcinoma obtained with Adriamycin. A case report with review of the literature. Cancer 43:1604–1606, 1979
de Jager R, Cappelaere P, Earl H, Rubens R, Harris RS, Smith I, Carmichael J, Smythe J, Keiling R, Renard J, van Glabbeke M, Mathe G: Phase II clinical trial of mitoxantrone: 1,4-dihydroxy-5–8-bis(((2-((2-hydroxyethyl)amino)-ethyl)amino)9,10 anthracenedione dihydrochloride in solid tumors and lymphomas. (Abstr) Proc Amer Soc Clin Oncol 1: 89, 1982
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr: Phase I clinical investigation of l-4-dihydroxy-5,8-bis-(((2-((2-hydroxyethyl)amino)ethyl)amino)9,10 anthracenedi-one dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980
Author information
Authors and Affiliations
Additional information
Address for offprints: Southwest Oncology Group (SWOG-8030), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA
Rights and permissions
About this article
Cite this article
Mattox, D.E., Von Hoff, D.D. & Balcerzak, S.P. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest New Drugs 8, 105–107 (1990). https://doi.org/10.1007/BF00216934
Issue Date:
DOI: https://doi.org/10.1007/BF00216934